CereVasc STRIDE Trial Randomizes First Patient to eShunt System

February 25, 2025—CereVasc, Inc. announced the randomization of the first patient in the multicenter STRIDE clinical trial of the company’s eShunt system. Neurosurgeon John Reavey-Cantwell, MD, treated the patient at VCU Health in Richmond, Virginia. Dr. Reavey-Cantwell is Director of Cerebrovascular and Endovascular Neurosurgery at VCU Health.

According to the company, the STRIDE trial is a head-to-head comparison of the safety and efficacy of the eShunt system versus standard-of-care ventriculoperitoneal (VP) shunt in elderly patients diagnosed with normal pressure hydrocephalus (NPH). Multiple trial site locations are now open across the United States, advised CereVasc. The results of the STRIDE trial will serve as the basis for CereVasc’s anticipated premarket approval submission to the FDA.

“I was honored to perform the inaugural treatment in the STRIDE trial,” commented Dr. Reavey-Cantwell in CereVasc’s press release. “This investigation could lead to a safer and less invasive way to address the gait disturbance, cognitive deficits, and urinary incontinence that are experienced by people with NPH.

“Because the eShunt system is less invasive than the VP shunt, this trial will assess its potential to improve recovery times and reduce postoperative complications such as infection. As a result, I’m hopeful it will make treatment possible for more patients living with this devastating neurological disease—including those who have comorbidities.”

CereVasc announced the commencement of the STRIDE trial on January 14, 2025, and advised that the trial will be conducted at sites in the United States and around the world. The company’s trial website is nphstridestudy.com.